21 May 2018

What if vitamin C reduced the effects of septic shock – an often deadly systemic inflammatory response? This is the avenue to be explored by the LOVIT clinical study, led by François Lamontagne, professor-researcher at the Université de Sherbrooke and the Centre de recherche du CHUS, and also critical care physician at the CIUSSS de l’Estrie CHUS.

800 Canadian and European patients will be participating in the research project, which aims to study the effect of heavy concentrations of vitamin C administered intravenously on mortality and the need for intensive care of patients with septic shock.

LOVIT has obtained a $2.8M grant from a Canadian non-profit organization and is assembling a team of fundamental specialists and researchers based at the University of Toronto and Queen’s University, as well as at the Université de Sherbrooke.

» Source and photo credit: Université de Sherbrooke